ARS Pharmaceuticals (NASDAQ: SPRY)
$10.28
(1.9%)
$0.19
Price as of October 2, 2025, 4:00 p.m. ET
ARS Pharmaceuticals Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
ARS Pharmaceuticals Company Info
ARS Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development of a novel, potentially first-in-class product candidate, neffy, for the emergency treatment of Type I allergic reactions including anaphylaxis. Its product includes Epinephrine Nasal Spray. The company was founded by Richard Lowenthal, Robert Bell, and Sarina Tanimoto on August 5, 2015 and is headquartered in San Diego, CA.
News & Analysis
Featured Article
ARS Pharma Sales Jump 3,040% in Q2
Motley Fool Markets Team | Aug 13, 2025
Featured Article
Why Shares of ARS Pharmaceuticals Are Plummeting on Wednesday
The company received a Complete Response Letter from the FDA regarding its lead therapy.
James Halley | Sep 20, 2023
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.